The role of lebrikizumab in the treatment of atopic dermatitis in the adult population

• Published in: Immunotherapy 2023-09, Vol.15 (13), p.981-991
• Main Authors: Prajapati, Stuti, Fardos, Mohammad, Desai, Amar D, Feldman, Steven R
• Format: Article
• Language: English
• Subjects: atopic dermatitis; biologics; eczema; IL-13; immunosuppressants; management
• ISSN: 1750-743X; 1750-7448
• DOI: 10.2217/imt-2023-0066

Although there are many atopic dermatitis (AD) treatments, finding a long-term medication with minimal side effects can be difficult. This review characterizes lebrikizumab as AD treatment in adults. A literature search was conducted to examine lebrikizumab's role in treating moderate to severe AD. In a phase III trial, 74% of adults with AD treated with lebrikizumab 250 mg every 4 weeks achieved an Investigator Global Assessment of 0/1, 79% achieved Eczema Area and Severity Index 75 and 79% experienced improvements in pruritus numeric rating scale scores relative to placebo. Common adverse effects in the ADvocate1 and ADvocate2 trials were conjunctivitis (7 and 8%, respectively), nasopharyngitis (4 and 5%, respectively) and headache (3 and 5%, respectively). Results from clinical trials suggest that lebrikizumab may be a viable alternative for AD management. Atopic dermatitis, commonly known as eczema, has a big impact on people's lives. There are many treatments for eczema, with new ones becoming available. In this review, we discuss lebrikizumab as a treatment for moderate to severe eczema in adults. We performed a literature search to better understand lebrikizumab's role in treating eczema. In clinical trials, lebrikizumab reduced itchiness and improved rash in adults with moderate to severe eczema. The most reported side effects were pink eye (conjunctivitis), the common cold (nasopharyngitis) and headache. Lebrikizumab is effective in relieving eczema symptoms with tolerable side effects and could be an alternative treatment for adults with moderate to severe eczema.